Cutting-edge imaging breakthroughs for early breast cancer detection
Peer-Reviewed Publication
Updates every hour. Last Updated: 9-Jul-2025 05:10 ET (9-Jul-2025 09:10 GMT/UTC)
The National Comprehensive Cancer Network® (NCCN®) announces 2025 awardees who go above and beyond to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.
Researchers at the Max Planck Institute for Biology of Ageing have discovered that the combination of the two cancer drugs Rapamycin and Trametinib significantly extends the lifespan of mice. This therapy shows greater effects than the individual drugs and offers not only a longer lifespan, but also health benefits in old age. The results suggest that this drug combination could be a promising strategy for combating age-related diseases and promoting longevity.
HOUSTON, MAY 28, 2025 ― Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), following treatment with the KRAS targeted therapy sotorasib.
Researchers from the University of Science and Technology of China report the first near-atomic-resolution structure of the human ATR–ATRIP complex bound to clinical inhibitors, providing critical insights into ATR regulation and inhibition.
- EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6.
- The Fast Track Designation highlights the potential of EBC-129 to address critical unmet needs in pancreatic ductal adenocarcinoma (PDAC).
- Updated clinical data from the ongoing Phase 1 study of EBC-129 will be presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Talin is a protein that plays an important role in the immune system by activating integrins, receptors that help cells attach to one another. Now a new study by Fox Chase Cancer Center researchers shows how talin has distinct binding modes for two types of integrins that are important in blood cells. It also highlights how switching modes can enhance the integrins, potentially making them stronger.
A new study, led by experts at the University of Nottingham, has found that young people suffering from certain types of cancer, such as bone tumours, are experiencing lengthy times to diagnosis.
The Childhood Cancer Diagnosis Study, which is published in the Lancet Regional Health - Europe, was funded by the National Institute for Health and Care Research (NIHR).
Childhood cancer has been declared a global disease burden, with early diagnosis a priority. The aim of this study was to help researchers understand the journey that children and young people experience from the start of their symptoms until they receive their cancer diagnosis.
To do this, the team of researchers, led by Dr Shaarna Shanmugavadivel, Professor Shalini Ojha and Professor David Walker from the School of Medicine at the University of Nottingham, collected the data of 1,957 children and young people (aged 0-18 years) diagnosed with cancer between September 2020 and March 2023.
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology Annual Meeting May 30 to June 3 in Chicago.